Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study

Ju Yeon Kim¹, Miso Kim², Jin Kyun Park¹, Eun Bong Lee¹, Jun Won Park¹* and Junshik Hong²*

Abstract

Background: Interleukin (IL)-6 is one of the key cytokines in the pathogenesis of secondary hemophagocytic lymphohistiocytosis (sHLH); however, the efficacy and safety of tocilizumab (TCZ), a monoclonal IL-6 receptor antibody, in patients with sHLH is uncertain.

Methods/Results: This study included 64 adult patients who were diagnosed with sHLH based on the HLH-2004 criteria. Patients were classified into two groups based on treatment regimen at baseline: tocilizumab (TCZ group, n = 8) versus other treatments (control group), including HLH-2004 protocol (n = 35), chemotherapy (n = 7), glucocorticoid alone (n = 8), and with other immunosuppressants (n = 6). Primary outcome was overall 8-week survival. Baseline characteristics between the two groups were comparable. At day 56, one patient (12.5%) in the TCZ group and twenty-eight patients (51.9%) in the control group survived. Univariable and multivariable Cox proportional hazard analysis showed that TCZ significantly increased the risk of death (adjusted hazard ratio 5.55; 95% CI 2.13–14.49). The complete or partial response rate at day 14 was 44.6% in the control group, and nil in the TCZ group. In contrast, infectious complications occurred more frequently in the TCZ group than in the control group (14.3% vs. 50.0%).

Conclusion: Our results suggest that tocilizumab has limited efficacy in treating adult patients with sHLH and could increase the risk of infectious complications compared to the conventional treatments.

Keywords: Secondary hemophagocytic lymphohistiocytosis, Interleukin-6, Tocilizumab, HLH-2004 protocol

Introduction

Hemophagocytic lymphohistiocytosis (HLH) is an aberrant hyper-inflammatory response characterized by excessive cytokine release and abnormal activation of macrophages and T cells, that eventually leads to devastating multi-organ failure [1, 2]. HLH is classified into two subtypes: primary and secondary HLH (sHLH). The former comprises a group of genetic disorders characterized either by loss-of-function mutations in granule-mediated cytotoxicity or by other congenital immunodeficiency syndromes, while the latter is a clinical syndrome that develops in the context of infections, malignancies, autoimmune/auto-inflammatory conditions, or immunotherapy [3, 4].

As untreated HLH is rapidly progressive and life-threatening, prompt initiation of HLH-specific treatment is essential for improved treatment outcomes and prognosis. The HLH-94 and HLH-2004 treatment protocols,

*Correspondence: mpersonality@gmail.com; hongjblood@snu.ac.kr

¹ Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Republic of Korea

² Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Republic of Korea

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
which include etoposide, dexamethasone, and cyclosporine, have been established as conventional therapies for pediatric HLH by international, prospective trials [5–7]. In contrast, no standardized treatment strategy has been delineated for HLH in adults on account of its rarity and heterogeneity, which has hampered the successful execution of large scale prospective clinical trials. Therefore, the treatment strategies for HLH in adults, mostly secondary, have been largely extrapolated from those used in pediatric HLH [8, 9]. However, concerns regarding pre-existing comorbidities in elderly patients and treatment-related toxicities such as infectious complications have prompted the search for alternative treatment strategies that target specific immune pathways or cytokine signaling [10–12].

Tocilizumab (TCZ) is a monoclonal antibody directed against the interleukin (IL)-6 receptor. IL-6 has been linked to cytokine release syndrome [13]. TCZ has demonstrated high efficacy and is approved by the U.S. Food and Drug Administration (FDA) for HLH-like cytokine release syndrome after chimeric antigen receptor T-cell (CAR-T) immunotherapy [14, 15]. The syndrome is characterized by marked elevation of IL-6, which is thought to play a key role in the characteristic cytokine storm. In COVID-19 infection, IL-6 levels correlate with disease severity, and anti-IL-6 therapy in critically ill patients demonstrated favorable efficacy in a few randomized trials [16–18]. Furthermore, TCZ was shown to be efficacious in patients with reactive HLH or macrophage activation syndrome (MAS) in a few case reports, suggesting that IL-6 blockade could be a potential therapeutic target in sHLH [11, 19]. The present study aimed to assess the efficacy and safety of IL-6 blockade by TCZ in adult patients with sHLH, as compared to conventional treatments.

**Methods**

**Patients**

This retrospective study included patients with sHLH who were treated at the Seoul National University Hospital between January 2004 and December 2019. A list of eligible patients was retrieved from the Seoul National University Hospital Patients Research Environment (SUPREME) (https://supreme.snuh.org). This system crosslinks ICD-9 and ICD-10 codes. Using a word “hemophagocytic,” which included patients with the ICD-10 codes of D76.1 and D76.2. Patients with ICD-10 code of D76.3 were additionally reviewed, and none of them had HLH. Fulfillment of at least five of the eight modified HLH-2004 criteria for hemophagocytic lymphohistiocytosis, namely fever, splenomegaly, bicytopenia (hemoglobin < 9 g/dL, platelet count < 100,000/µL, absolute neutrophil count < 1,000/µL), hypertriglycerideremia or hypofibrinogenemia, elevated serum ferritin > 3,000 ug/L, elevated soluble IL-2 receptor > 2,400 units/mL, low or absent natural killer cell cytotoxicity, and tissue demonstration of hemophagocytosis led to inclusion in the study [6, 10, 20]. All patients younger than 18 years of age, those without available medical records, and those that were diagnosed with pHLH were excluded.

The study was approved by the Seoul National University Hospital Institutional Review Board (IRB approval number: 2105-107-1219), and all research was performed in accordance with relevant guidelines/regulations. Informed consent was waived by the IRB due to the retrospective nature of the study.

**Clinical data**

All medical records of eligible patients regarding their demographic details, medication history, laboratory and radiographic investigations, adverse events, and the date and cause of death were collected. The H-score was calculated based on a set of weighted criteria as described by Fardet et al. [21]. The baseline date was defined as the date when a specific treatment for sHLH (index treatment) was initiated. Included patients were classified into two groups based on the treatment regimen initiated at baseline, which was either TCZ treatment or all other treatments including the HLH-2004 protocol, other chemotherapeutic agents, and glucocorticoids with or without other immune modulating agents (i.e., TCZ group vs. control group).

**Response assessment**

Treatment response was assessed by evaluation of all medical records of clinical and laboratory findings that were maintained daily until the date of discharge and weekly thereafter until week 8. Treatment response was assessed based on the following clinical parameters: 1) complete blood count profile, 2) coagulopathy, 3) neurologic manifestations, 4) hepatitis and/or hyperbilirubinemia, 5) hemodynamic instability, 6) renal insufficiency, 7) hepatosplenomegaly and 8) fever. A complete response (CR) was defined as the normalization of all abnormal clinical and laboratory findings. An improvement of at least 25% in two or more abnormal clinical or laboratory findings was defined as a partial response (PR), while a worsening of more than 50% in two or more of the same was categorized as progressive disease (PD). Patients who fulfilled neither of these criteria were classified as having stable disease (SD) [10]. The primary outcome of the study was overall eight-week survival. Secondary outcomes included the proportion of patients who achieved an overall response (including CR and PR) and the proportion of patients who experienced the composite outcome (PD and death) at D14, D28, and D56. In addition,
the occurrence of infectious complications was assessed throughout the observation period.

**Statistical analysis**

We performed an intention-to-treat analysis for all efficacy and safety assessments. Continuous or dichotomous baseline data were compared using the Wilcoxon rank sum test or Fisher’s exact test, as appropriate. Overall survival between the two groups was compared using the log-rank test and the Cox proportional hazard model. Efficacy outcomes between the two groups were analyzed using a binary logistic regression analysis. In the multivariable analysis, clinical factors with relevant associations ($P < 0.1$) with the outcome in the univariate analysis were included as covariates. Firth’s penalized maximum likelihood was used when the outcome variables showed a complete separation.

All statistical analyses were performed using IBM SPSS version 26 (IBM Corp., Armonk, NY, USA). Statistical significance was set at $P < 0.05$.

**Results**

**Baseline characteristics**

A total of 77 patients with sHLH who fulfilled the HLH-2004 diagnostic criteria were included in the study. Among them, 13 patients were excluded because they experienced rapid disease progression and early death before the initiation of any treatment for sHLH. The remaining 64 patients who received at least one HLH-targeted treatment were analyzed. Of these, eight patients received TCZ as the first-line therapy (TCZ group)—four patients received doses of 4 mg/kg, two received 8 mg/kg, and one received 6 mg/kg. Only two of these patients survived long enough to receive a second dose of TCZ two weeks following the initial dose; the rest only received TCZ once (Additional file 1: Table S1). Fifty-six patients received treatments other than TCZ (control group), which consisted of HLH-2004 regimen ($n = 35$), malignancy targeted chemotherapy ($n = 7$), glucocorticoid alone ($n = 8$), and other immunosuppressive therapies ($n = 6$). Four of whom initially treated with HLH-2004 protocol subsequently received cancer-specific chemotherapy. None of the patients in the control group received Janus kinase (JAK) inhibitors, such as ruxolitinib, at baseline. The inclusion and exclusion criteria as well as the list of individual treatments given to the controls are presented in Additional file 1: Fig. S1.

Baseline characteristics are listed in Table 1. The etiologies of sHLH were comparable, but the control group had a greater number of patients with malignancies. All cases were experiencing the first episode of sHLH except for one case in the TCZ group, in which disease had been reactivated after a period of remission. The patients who were diagnosed with malignancy associated HLH initiated baseline treatment earlier (mean $29.2 \pm 15.7$ days vs. mean $45.3 \pm 31.0$ days, $P = 0.048$).

There were no significant differences in the clinical features at baseline between the two groups. The median interquartile range (IQR) and $H$-score was 247.0 and 64 respectively for the control group and 237.0 and 33 respectively for the TCZ group, both of which indicated a greater than 98% probability of HLH [21]. Azotemia, defined as estimated glomerular filtration rate (eGFR)<60, was seen in 19.6% (11/56) of the control group, and 25% (2/8) of the TCZ group, and both groups had a mean Model for End-Stage Liver Disease (MELD) score of greater than 11 at baseline. The mean (SD) time interval from symptom onset to baseline in the control and TCZ group were 41.0 (29.4) and 33.9 (15.0) days, respectively, which were not significantly different ($P = 0.730$). Prior to sHLH targeting therapy at baseline, all eight patients (100.0%) in the TCZ group and 37 of the 56 (66.1%) patients in the control group were receiving glucocorticoid. After initiating the index treatment, TCZ or control therapies, all patients in both groups concomitantly started high dose glucocorticoid, at a dose of at least 1 mg/kg prednisolone equivalent dose.

**Treatment responses**

At eight weeks from baseline, 12.5% (1/8) of the patients in the TCZ group and 51.9% (27/52) of the patients in the control group had survived. All deaths were attributable to the progression of sHLH and/or its associated complications, which were mostly infections. The cause of death and the duration of survival of the patients in the TCZ group are presented in Additional file 1: Table S1. Univariable Cox proportional hazard analysis revealed that TCZ was significantly associated with an increased risk of death at D56 (hazard ratio [HR] 2.92; 95% CI 1.25–6.82) (Table 2). This result was consistent with that observed in the multivariable analysis, in which relevant clinical factors were included as covariates (adjusted HR = 5.55; 95% CI 2.13–14.49) (Fig. 1, Table 2). Regarding the underlying etiologies, rheumatic disease, malignancy, and infection were not significantly associated with an increased risk of death at D56.

The overall response rates in the control group at D14, D28, and D56 were 44.6% (25/56), 50.0% (27/54), and 44.2% (23/52), respectively. A complete response was achieved in 8.9% (5/56) in D14, 20.4% (11/54) in D28, 36.5% (19/52) in D56; a partial response was observed in 35.7% (20/56), 29.6% (16/54), and 7.7% (4/52), respectively. In contrast, no patient showed a partial or complete response at D14 in the TCZ group (Fig. 2). Only one patient, who switched from TCZ to the HLH-2004 regimen at D15 and to ruxolitinib at D35 due to limited
response to treatment, had a favorable response at D28 (PR) and D56 (CR) in the TCZ group.

By D56, composite outcome had occurred in 87.5% (7/8) of the patients in the TCZ group and 53.9% (28/52) of the patients in the control group (Fig. 2). The univariable and multivariable logistic regression analyses revealed that TCZ treatment significantly increased the risk of composite outcome at D56 (adjusted OR 12.93; 95% CI 1.16–144.05) (Additional file 1: Table S2). In addition, the TCZ group was also significantly associated with more frequent composite outcomes at D14 (Additional file 1: Table S3) and D28 (Additional file 1: Table S4).

Infectious complication
A total of 24 patients experienced at least one infectious complication during the observation period. The most common infection was bacteremia (n = 12), followed by pneumonia/lower respiratory tract infections (n = 11) and fungemia (n = 8) (Table 3). The proportion of patients who experienced at least one infectious complication was higher in the TCZ group (62.5%) as compared to the control group (33.9%), with a P value of 0.139. The patients who had malignancy associated HLH had a lower number of infections during the treatment course (16.7% (3/18) vs 45.7% (21/46), P = 0.031). At the time of infection, 14 of 19 (73.7%) in TCZ group and 3 of 5

| Table 1 | Baseline characteristics of the patients |
|---------|----------------------------------------|
|         | Control group (n = 56) | TCZ group (n = 8) | P  |
| Age, years, n | 47.3 (17.5) | 48.5 (19.7) | 0.871 |
| Sex, male, n | 24 (42.9) | 4 (50.0) | 0.721 |
| Cause of HLH | | | |
| Rheumatic disease | 9 (16.1) | 3 (37.5) | 0.164 |
| Malignancy | 17 (30.4) | 1 (12.5) | 0.424 |
| Infection | 13 (23.2) | 2 (25.0) | 1.000 |
| Idiopathic | 18 (32.1) | 1 (12.5) | 0.418 |
| ICI | 0 (0) | 1 (12.5) | 0.125 |
| Symptom-to-treatment interval, days | 41.0 (29.4) | 33.9 (15.0) | 0.730 |
| Prior chemotherapya | 1 (1.8) | 1 (12.5) | 0.236 |
| Prior immunosuppressanta | 4 (7.1) | 2 (25.0) | 0.159 |
| Glucocorticoid before baseline, n | 37 (66.1) | 8 (100) | 0.093 |
| Baseline Glucocorticoid dose, mg/dayb | 112.9 (49.0) | 113.3 (21.4) | 0.396 |
| Baseline clinical factors | | | |
| Fever | 54 (96.4) | 8 (100.0) | 1.000 |
| Hepatosplenomegaly | 50 (89.3) | 8 (100.0) | 1.000 |
| CNS manifestationc | 15 (26.8) | 3 (37.5) | 0.676 |
| Hepatitis | 49 (87.5) | 6 (75.0) | 0.312 |
| Shock | 28 (50.0) | 4 (50.0) | 1.000 |
| Azotemia | 11 (19.6) | 2 (25.0) | 0.660 |
| Coagulopathy | 47 (83.9) | 8 (100.0) | 0.587 |
| H-score | 243.3 (36.8) | 233.6 (20.1) | 0.422 |
| GFR, mL/min/1.73 m² | 108 (77.3) | 106.1 (75.5) | 0.984 |
| MELD score | 12.5 (7.2) | 12.2 (9.2) | 0.509 |
| ANC, /μL | 2619.8 (5898.6) | 4691.5 (5472.0) | 0.345 |
| Hemoglobin, g/dL | 8.6 (2.1) | 9.7 (3.0) | 0.477 |
| Platelet, x10³/μL | 50.5 (34.4) | 59.0 (40.7) | 0.670 |
| Ferritin, μg/L | 27,827.6 (55,539.4) | 20,873.7 (15,333.7) | 0.283 |
| Fibrinogen, mg/dL | 161.4 (125.3) | 155.1 (90.6) | 0.879 |

Data are presented as the mean (SD) or n (%)
ANC, absolute neutrophil count; CNS, central nervous system; GFR, glomerular filtration rate; HLH, hemophagocytic lymphohistiocytosis; ICI, immune checkpoint inhibitor; MELD, Model For End-Stage Liver Disease; TCZ, tocilizumab.

a Defined as any prior history of chemotherapy or immunosuppressant prescription before the baseline treatment
b Presented as prednisolone equivalent dose
c An altered level of consciousness
**Table 2** Clinical factors associated with 8-week overall survival

| Clinical factors                                      | Univariable analysis | p       | Multivariable analysis* | p       |
|------------------------------------------------------|----------------------|---------|-------------------------|---------|
|                                                      | HR (95% CI)          |         | HR (95% CI)             |         |
| Clinical factors                                     |                      |         |                         |         |
| Age†                                                 | 1.03 (1.00–1.05)     | **0.020**| 1.00 (0.98–1.03)        | 0.714   |
| Male sex                                             | 0.68 (0.34–1.36)     | 0.272   |                         |         |
| Symptom duration, days†                               | 1.00 (0.99–1.01)     | 0.450   |                         |         |
| Steroid use prior to the treatment                   | 0.84 (0.39–1.81)     | 0.653   |                         |         |
| Baseline MELD†                                       | 1.09 (1.04–1.14)     | **<0.001**| 1.09 (1.03–1.16)       | **0.005**|
| Baseline GFR, mL/min/1.73 m²†                         | 0.99 (0.99–1.00)     | **0.064**| 1.00 (1.00–1.01)        | 0.623   |
| Baseline H-score†                                     | 1.00 (0.99–1.01)     | 0.524   |                         |         |
| Baseline fibrinogen, mg/dL†                           | 1.00 (0.99–1.00)     | 0.144   |                         |         |
| Underlying cause                                     |                      |         |                         |         |
| Rheumatic disease                                    | 0.93 (0.38–2.25)     | 0.864   |                         |         |
| Malignancy                                           | 0.49 (0.20–1.20)     | 0.119   |                         |         |
| Infection                                            | 0.82 (0.35–1.88)     | 0.632   |                         |         |
| Idiopathic                                           | 2.21 (1.09–4.49)     | **0.028**| 2.44 (1.11–5.36)       | **0.027**|
| Treatment at baseline                                |                      |         |                         |         |
| HLH-2004 regimen                                     | 0.69 (0.35–1.39)     | 0.302   |                         |         |
| Chemotherapy                                         | 0.36 (0.09–1.52)     | 0.166   |                         |         |
| Other immunosuppressant                               | 0.54 (0.13–2.26)     | 0.400   |                         |         |
| Steroid only                                         | 3.21 (1.30–7.95)     | **0.012**| 2.85 (0.98–8.30)       | 0.056   |
| Tocilizumab                                          | 2.92 (1.25–6.82)     | **0.013**| 5.55 (2.13–14.49)      | **<0.001**|

Bold text indicates a statistically significant difference with a p-value less than 0.05

* Adjusted for clinical factors with relevant association (P < 0.1) in univariable analysis
† The variable was included in the model as a continuous variable

GFR, glomerular filtration rate; HLH, hemophagocytic lymphohistiocytosis; MELD, Model For End-Stage Liver Disease

---

**Fig. 1** Treatment response at D14, D28, and D56 was assessed as complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or death in the two groups.

* One patients in the TCZ group showed SD at D14 but progressed afterward and switched to HLH-2004 regimen (D15) and ruxolitinib (D36).
(60%) in control group, were neutropenic \( (P = 0.608) \). As many as 14 patients were infected with multiple strains of microorganisms simultaneously, and the proportion of such patients was higher in the TCZ group than in the control group \( (50\% \text{ vs. } 17.9\%, P = 0.062) \). The proportion of patients who were detected with bacteremia was significantly higher in the TCZ group.

There were standardized anti-microbial prophylaxis for HLH-2004 protocol and high dose glucocorticoid. There was no standardized anti-microbial prophylaxis protocol for TCZ infusion. Nevertheless, of the 8 patients who received TCZ, 6 were receiving broad spectrum empirical antibiotics and 5 were receiving antifungal agents, because these patients were experiencing recurrent fever and/or neutropenia.

**Sensitivity analysis**

At the first instance, we only included patients who were treated with the HLH-2004 regimen in the control group and compared the eight-week overall survival between this group and the TCZ group. Both univariate and multivariate analyses showed that the TCZ group was significantly associated with a poor prognosis (Additional file 1: Table S5 and Fig. S2). Next, we compared the overall survival, after defining the baseline date as the date of symptom onset to account for the possible confounding effect of delayed treatment. The results thus obtained were consistent with those seen in the original Cox regression analysis (Additional file 1: Table S6 and Fig. S3). Lastly, we evaluated the HLH response based on a set of response criteria described in the emapalumab study [22]. As consistent with our study, the TCZ group had a lower response rate than the control group, although not statistically significant. At D56, 42.9% \( (24/56) \) and 12.5% \( (1/8) \) of control and TCZ group respectively had overall response, which consist of CR, PR, and improvement (adjusted OR 0.11 [0.01 to 1.30], \( P = 0.113) \) (Additional file 1: Fig. S4).

**Discussion**

To the best of our knowledge, this is the first study that investigates the safety and efficacy of IL-6R inhibition in comparison to conventional treatments in patients with sHLH. A higher proportion of patients in the TCZ group experienced disease progression and showed a poor survival rate as compared to those in the control group. Furthermore, infectious adverse events occurred more frequently in the TCZ group. These results suggest that the safety and efficacy of TCZ is not favorable in patients with sHLH as compared to conventional treatment options.

As hypercytokinemia is a pathological hallmark of HLH, and consequently cytokine-targeted therapies are of particular interest in this era of biologic therapies, the results of this study are significant. However, selective neutralization of a single cytokine within the panoply of cytokines engaged in HLH may not always be effective in terminating disease progression. Tumor necrosis factor-\( \alpha \), interferon-\( \gamma \), and various interleukins, including IL-1, IL-2, IL-6, and IL-18, have been linked to the cytokine cascade implicated in sHLH, and each of these cytokines has a complex interconnection with each other, that is not fully understood [23, 24]. Among the cytokine

| Table 3 | Infectious complication during the observation period |
|---------|-----------------------------------------------------|
|         | Control group \((n = 56)\) | TCZ group \((n = 8)\) | \( P \) |
| At least one infectious complication | 19 (33.9) | 5 (62.5) | 0.139 |
| Bacteremia | 8 (14.3) | 4 (50.0) | 0.035 |
| Fungemia | 5 (8.9) | 3 (37.5) | 0.054 |
| Pneumonia/lower-respiratory tract infection | 10 (17.9) | 1 (12.5) | 1.000 |
| GI infection | 4 (7.1) | 0 (0.0) | 1.000 |
| Other infections | 3 (5.4) | 0 (0.0) | 1.000 |
| Infection of unknown focus | 1 (1.8) | 0 (0.0) | 1.000 |

GI, Gastrointestinal; TCZ, tocilizumab
mille, IL-6 is a part of the downstream cascade induced by IL-1β and IL-18, rather than a driver cytokine. Therefore, it is uncertain if treatment with TCZ alone has a significant effect on the various inflammatory cytokines involved in sHLH. Moreover, despite the typical IL-6 elevation in the preclinical models of sHLH and other cytokine release syndromes, the role of IL-6 in the pathogenesis of HLH remains unclear. A previous study on the cytokine pattern in HLH showed that IL-6 is only modestly elevated in HLH, contrary to what was observed for other key cytokines [25]. It is of note that two dermatomyositis patients in the TCZ group also had a poor treatment outcome. Previous studies suggested that dermatomyositis-related MAS is associated with high mortality rate but no standard treatment strategy has been established yet [26, 27]. Although a few studies reported cases of anti-MDA-5 myopathic dermatomyositis complicated by MAS that were successfully treated with TCZ, these patents were concomitantly treated with glucocorticoid and other immunosuppressants, such as cyclosporine and rituximab [28]. Considering that excessive type I interferon activity, of which most up-regulated in patients with dermatomyositis, has also been implicated in a HLH-like syndrome, targeting IL-6 alone may not be sufficient in controlling disease activity [29, 30]. In light of these findings, clinicians should be precautious when using TCZ as a monotherapy in patients with dermatomyositis-related MAS.

As all the patients in the TCZ group were treated with TCZ as the frontline therapy, the poor prognosis in this group is attributable to the limited efficacy of TCZ, rather than to the selection of refractory cases in the TCZ group. Our result is contrary to that reported in a recent case series, which showed clinical remission in eight of nine sHLH patients treated with TCZ [11]. However, the time to reach remission, response duration, and time interval to death were not clearly described in the same study. Furthermore, four (50.0%) of the patients who achieved remission eventually died during hospitalization, and another three patients developed septic shock. This finding is in line with our result that 62.5% of the patients in the TCZ group experienced at least one infectious complication. Similar trends have been reported in other studies [31, 32]. Lang et al. reported that patients treated with TCZ showed higher rates of infectious complication [31]. Furthermore, a recent study on patients with COVID-19 related cytokine release syndrome demonstrated that late-onset infections (>48 h following admission) were more common among those who received TCZ [26]. Although the cause of this phenomenon is undeciphered, discrepancies in the levels of acute phase reactants such as C-Reactive Protein following the administration of TCZ, which might mask the typical signs of infection and therefore delay diagnosis have been previously reported [32, 33].

Contrary to previous reports, overall survival in patients with malignancy-associated HLH was not inferior to that in those with other underlying diseases [34–36]. It could be attributable to the fact that patients with non-malignancy associated HLH were diagnosed at a later stage of the disease. This delay in diagnosis could lead to delay in treatment and consequently more complications before the treatment. In fact, the patients who were diagnosed with malignancy associated HLH initiated baseline treatment earlier and had a lower number of infections during the treatment course. A similar result was observed in a case series performed in Latin America [37].

This present study has several limitations. First, on account of the study not being a randomized study, its results could be biased by “confounding by indication.” Although we have demonstrated that the baseline characteristics such as duration of symptoms, clinical manifestations, and H-score were comparable between the two groups, imbalances of unmeasured factors such as preferences of the treating physicians could have influenced the outcome. Second, the number of patients in the TCZ group was relatively small, which was not unexpected given the rarity of the disease. A small sample size could lead to an overestimation of effect size and low reproducibility. Although we repeatedly found inferior outcome associated with TCZ treatment in sHLH after performing several sensitivity analyses, the results should be consistently replicated and verified in subsequent studies before being put into real practice. Third, the patients in TCZ group were more recently treated when compared to the control. However, this time difference did not shift the bias toward the positive outcome of TCZ. Finally, the sample size of this study was too small to perform a meaningful subgroup analysis that can be stratified based on etiology or specific individual treatment regimen.

Conclusion
In summary, our results suggest that TCZ treatment has limited efficacy and is associated with an increased risk of infectious complications as compared to conventional treatment in patients with sHLH. Although the safety and efficacy of TCZ should be further investigated and clarified by randomized studies in the future, its use should be reconsidered until robust evidence supporting its application for treatment of sHLH emerges.

Abbreviations
CR: Complete response; HR: Hazard ratio; HLH: Hemophagocytic lymphohistiocytosis; IRB: International review board; IL: Interleukin; PR: Partial response; pHLH: Primary hemophagocytic lymphohistiocytosis; PD: Progressive disease;
sHLH: Secondary hemophagocytic lymphohistiocytosis; SD: Stable disease; TCZ: Tocilizumab.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13023-022-02516-1.

Additional file 1. Supplement Material: supplementary figure S1 to S3 and supplementary table S1 to S6. Supplementary figure S1. Flow of patient inclusion. Supplementary table S1. Summary of patients in the tocilizumab group. Supplementary table S2. Risk factor for composite outcome at D56. Supplementary table S3. Risk factor for composite outcome at D14. Supplementary table S4. Risk factor for composite outcome at D28. Supplementary table S5. Clinical factors significantly associated with 56-day overall survival in the subgroup of patients who were treated with tocilizumab or HLH-2004 regimen. Supplementary figure 2. Kaplan-Meier curve comparing Day 56 overall survival in the subgroup of patients - tocilizumab versus HLH-2004 regimen. Supplementary table S6. Clinical factors significantly associated with overall survival from the onset of initial HLH-related symptom. Supplementary figure 3. Kaplan-Meier curve between the two groups from the onset of initial HLH-related symptom.

Acknowledgements

Not applicable.

Author contributions

JWP and JSH contributed to the study conception and design. JYK was responsible for the data acquisition, statistical analysis, and writing the manuscript. All authors contributed to data interpretation, writing and critical revision of the manuscript. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by the International Review Board of Seoul National University Hospital (2105-107-1219). Informed consent was waived due to the retrospective nature of the study.

Consent for publication

Not applicable.

Competing interests

The authors have declared no conflicts of interest.

Received: 15 June 2022 Accepted: 4 September 2022
Published online: 21 September 2022

References

1. Hayeden A, et al. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: a systematic scoping review. Blood Rev. 2016;30(6):411–20.
2. Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015;125(19):2908–14.
3. Chandrakasan S, Filipovich AH. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr. 2013;163(5):1253–9.
4. Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev. 2015;26(3):263–80.
5. Bergsten E, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728–38.
6. Henter JI, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.
7. Trottestam H, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577–84.
8. La Rosee P, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465–77.
9. Ramos-Casals M, et al. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503–16.
10. Ahmed A, et al. Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019;6(12):e630–7.
11. Dufranc E, et al. IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome. Crit Care. 2020;24(1):166.
12. Wohlfarth P, et al. Interleukin 1 receptor antagonist anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically ill adult patients with hemophagocytic lymphohistiocytosis. J Intensive Care Med. 2019;34(9):723–31.
13. Tanaka T, Narasaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959–70.
14. Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T-cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15(8):813–22.
15. Neelapu SS, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(11):47–62.
16. Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–45.
17. Investigators R-C, et al. Interleukin-6 receptor antagonists in critically ill patients with covid-19. N Engl J Med. 2021;384(16):1491–502.
18. Salama C, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20–30.
19. Faguer S, et al. Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme + T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis. Hematol Oncol. 2016;34(1):SS–7.
20. Jordan MB, et al. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041–52.
21. Fardet L, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–20.
22. Locatelli F, et al. Empalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382(19):1811–22.
23. Crayne CB, et al. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119.
24. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255–73.
25. Xu XJ, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. 2012;160(6):984-90 e1.
26. Ding Y, Ge Y. Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis complicated with macrophage activation syndrome. Ther Adv Chronic Dis. 2022;13:20406223221098130.
27. Liang J, et al. Hemophagocytic lymphohistiocytosis: prevalence, risk factors, outcome, and outcome-related factors in adult idiopathic inflammatory myopathies. J Rheumatol. 2020;47(10):1532–40.
28. Su CF, Liao HT, Tsai CY. Tocilizumab and rituximab for anti-MDA-5 positive amyopathic dermatomyositis complicated with macrophage activation syndrome and progressive fibrosing interstitial lung disease. Scand J Rheumatol. 2022;51(2):166–8.
29. Pinal-Fernandez I, et al. Identification of distinctive interferon gene signatures in different types of myositis. Neurology. 2019;93(12):e1193–204.
30. Duncan CJA, et al. Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2. Sci Immunol. 2019;4(42):eaav7501.
31. Lang VR, et al. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford). 2012;51(5):852–7.
32. Pettit NN, et al. Late onset infectious complications and safety of tocilizumab in the management of COVID-19. J Med Virol. 2021;93(3):1459–64.
33. Berman M, et al. The effect of tocilizumab on inflammatory markers in patients hospitalized with serious infections. Case series and review of literature. Life (Basel). 2021;11(3):258.
34. Parikh SA, et al. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014;89(4):484–92.
35. Li J, et al. Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients. Medicine (Baltimore). 2014;93(2):100–5.
36. Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015;90(3):220–4.
37. Apodaca E, et al. Prognostic factors and outcomes in adults with secondary hemophagocytic lymphohistiocytosis: a single-center experience. Clin Lymphoma Myeloma Leuk. 2018;18(10):e373–80.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.